Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CMS in $70 Million Deal for French Thrombotic Therapy

publication date: Aug 1, 2018

China Medical Systems of Shenzhen announced a $70-plus million agreement for China rights to a clinical-stage thrombotic drug from France's Acticor Biotech. ACT017 is a humanized monoclonal antibody fragment (Fab) directed against a platelet glycoprotein (GPVI) involved in thrombosis, intended to treat stroke and pulmonary embolism. Part of the $70 million will be invested in an Acticor subsidiary. CMS will have development, manufacturing and commercialization rights to ACT017 in China and Asia (except for Japan and India). More details....

Stock Symbol: (HK: 0867)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.